ValuEngine downgraded shares of Chimerix, Inc. (NASDAQ:CMRX) from a sell rating to a strong sell rating in a research report released on Thursday.

Separately, Zacks Investment Research upgraded shares of Chimerix from a hold rating to a buy rating and set a $5.25 price objective for the company in a research report on Wednesday, August 9th.

Chimerix (CMRX) traded up $0.14 during trading on Thursday, reaching $4.90. 139,200 shares of the company traded hands, compared to its average volume of 217,652. Chimerix has a 52-week low of $4.28 and a 52-week high of $6.64.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.81 million. analysts predict that Chimerix will post -1.65 EPS for the current year.

WARNING: “Chimerix, Inc. (CMRX) Downgraded by ValuEngine” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/chimerix-inc-cmrx-downgraded-by-valuengine/1698885.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Chimerix during the first quarter valued at about $226,000. Dimensional Fund Advisors LP increased its position in shares of Chimerix by 114.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after acquiring an additional 557,927 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Chimerix by 11.7% during the first quarter. Geode Capital Management LLC now owns 341,238 shares of the biopharmaceutical company’s stock valued at $2,177,000 after acquiring an additional 35,752 shares during the last quarter. AXA increased its position in shares of Chimerix by 284.9% during the second quarter. AXA now owns 258,573 shares of the biopharmaceutical company’s stock valued at $1,409,000 after acquiring an additional 191,400 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Chimerix by 7.0% during the first quarter. Bank of New York Mellon Corp now owns 245,080 shares of the biopharmaceutical company’s stock valued at $1,564,000 after acquiring an additional 16,117 shares during the last quarter. Institutional investors and hedge funds own 67.56% of the company’s stock.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.